Assessment of Fibroblast Growth Factor- 23 and Klotho Protein in Children with Steroid-Sensitive Nephrotic Syndrome and Steroid-Resistance Nephrotic Syndrome
DOI:
https://doi.org/10.31351/vol34iss3pp173-181Keywords:
fibroblast growth factor-23, klotho, idiopathic nephrotic syndrome, Frequent relapseAbstract
Idiopathic nephrotic syndrome is a common disease that affects children’s kidneys and occurs due to a specific defect in the glomeruli, which leads to the leakage of protein into urine in large quantities. Fibroblast growth factor-23 (FGF-23), produced by bone, is essential for controlling the metabolism of 1,25-dihydroxy vitamin D and phosphate, but it also requires the Klotho co-receptor to perform its function. Therefore, the purpose of this study was to evaluate whether FGF-23 can be used as a biomarker to determine the likelihood of recurrent relapse as well as to differentiate between steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS) treated with glucocorticosteroids. In this cross-sectional study, 85 patients with idiopathic nephrotic syndrome were divided into four groups: Out of 50 children included in this study with (SSNS) were grouped in the first group (20) in relapse and the second (30) in remission, in addition to 35 child had (SRNS) were divided as: the third group of (20) in the relapse phase and the fourth group of (15) in the remission phase, while the control group included 40 healthy children. The fibroblast growth factor (FGF-23) levels and its co-receptor Klotho were measured in these patients using an ELISA kit. Our results revealed that serum levels of FGF-23 were significantly elevated in steroid-sensitive NS with a mean of (51.73 ng/L) in relapse and (16.49 ng/L) in remission, while for the steroid-resistant groups (67.25 ng/L) in relapse and (24.66 ng/L) in remission, compared with the control group with a mean of 7.73 ng/L (P < 0.0001). At the same time, Klotho concentrations were decreased for all patient groups compared with the control group. Hence, FGF-23 serum level is a potential biomarker to identify patients with frequent relapses at a cutoff value (16.055 ng/L). While its ability to distinguish between SSNS and SRNS patients was lower at a cut-off value of (20.00 ng/L).
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Al-Mendalawi MD. Thyroid Dysfunction in Children with Idiopathic Nephrotic Syndrome Attending a Paediatric Hospital in Qazvin, Iran. SQU Med J. 2021; 21:e332.
Mohammed A, Alridha A, Kadhim DJ, Hussein A, Alkhazrajy A. The Potential of Vitamin-D-Binding Protein as a Urinary Biomarker to Distinguish Steroid-Resistant from Steroid-Sensitive Idiopathic Nephrotic Syndrome in Iraqi Children. Siriraj Med J. 2023;75:248–58.
Azat NFA. Evaluation of Serum (immunoglobulin G, M) in children with nephrotic syndrome relapse. J Fac Med Baghdad. 2012;54:15–7.
Hanoudi BM, Mohammed R, AL-Kaissi KW. Study of Factors Associated with Childhood Nephrotic Syndrome, Frequent Relapsing and Infrequent Relapsing Type. Al-Kindy Coll Med J. 2014;10:71–7.
Latic N, Erben RG. FGF23 and Vitamin D Metabolism. JBMR Plus. 2021;5:1–7.
Ratsma DMA, Zillikens MC, van der Eerden BCJ. Upstream Regulators of Fibroblast Growth Factor 23. Front Endocrinol (Lausanne). 2021;12:588096.
Bär L, Stournaras C, Lang F, Föller M. Regulation of fibroblast growth factor 23 (FGF23) in health and disease. FEBS Lett. 2019;593:1879–900.
Erben RG, Andrukhova O. FGF23-Klotho signaling axis in the kidney. Bone. 2017; 100:62–8.
Toro L, Conejeros C, Ayala P, Parra-lucares A, Ahumada F, Almeida P, et al. A Combined Biomarker That Includes Plasma Fibroblast Growth Factor 23, Erythropoietin, and Klotho Predicts Short- and Long-Term Morbimortality and Development of Chronic Kidney Disease in Critical Care Patients with Sepsis: A Prospective Cohort. Biomolecules. 2023;13:1–14.
Calvo M S, Dunford EK, and Uribarri J. Industrial Use of Phosphate Food Additives: A Mechanism Linking Ultra-Processed Food Intake to Cardiorenal Disease Risk? Nutrients. 2023;15:2–14.
Jiang J, Liu Q, Mao Y, Wang N, Lin W, Li L, et al. Klotho reduces the risk of osteoporosis in postmenopausal women: a cross ‑ sectional study of the National Health and Nutrition Examination Survey (NHANES). BMC Endocr Disord. 2023;23:1.
Trzewik PP, Czechowska E, Stachowicz K, Sowa-Ku´cma M. The Importance of α -Klotho in Depression and Cognitive Impairment and Its Connection to Glutamate Neurotransmission — An Up-to-Date Review. Int J Mol Sci. 2023;24:2–22.
Latic NL, and Erben RG. Interaction of Vitamin D with Peptide Hormones with Emphasis on Parathyroid Hormone, FGF23, and the Renin-Angiotensin-Aldosterone System. Nutrients. 2022;14:1–18.
Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. 2015;16:165–74.
Burnett-Bowie SAM, Henao MP, Dere ME, Lee H, Leder BZ. Effects of hPTH (1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res. 2009;24:1681–5.
David V, Dai B, Martin A, Huang J, Han X, Quarles LD. Calcium regulates FGF-23 expression in bone. Endocrinology. 2013;154:4469-82.
Al-taiee TAK, Al-shammaa NMJ. Effect of Anti Diuretic Hormon (ADH) in Kidney Function on Post Hemodialysis End Stage Renal Failure Disease (ESRD) Iraqi Patients. Iraqi J Sci. 2018;59:1372–7.
Baroncelli GI, Sessa MR, Pelosini C, Bertelloni S, Michelucci A, Toschi B, Piaggi P, Peroni D, Comberiati P. Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X-linked hypophosphatemic rickets. J Endocrinol Invest. 2024;47:873-882.
Al-taiee TAK. Study of the Anti-Diuretic Hormone (ADH) on End Stage Renal Failure Disease (ESRD) Pre-Hemodialysis in Iraqi Patients. Ibn Al-Haitham Jour Pure Appl Sci. 2019;32:30-37.
Soriano S, Ojeda R, Rodríguez M, Almadén Y, Rodríguez M, Martín-Malo A, et al. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol. 2013;80:17–22.
Starcea IM, Bogos RA, Scurtu G, Munteanu M, Russu R, Lupu VV, et al. Pathological and Evolutive Correlations in Steroid Resistant Nephrotic Syndrome in Children. Int J Gen Med. 2022;15:4187–93.
Jaber BA et al. COMPLICATIONS OF NEPHROTIC SYNDROME IN CHILDREN. Wiad Lek. 2022;75:2226–32.
Al-kinani ZA, Ali SH. Serum Chitotriosidase Level as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis among the Iraqi children. Iraqi J Pharm Sci. 2021;30:270–6.
Pukajło-Marczyk A, Jakubowska A, Bargenda-Lange A, Kiliś-Pstrusińska K, Zwolińska D. Assessment of the concentration of bone metabolism markers: Sclerostin and FGF-23 in children with idiopathic nephrotic syndrome treated with glucocorticosteroids. Dis Markers. 2019; 2019:9698367.
Ammar YA, Maharem DA, Mohamed AH, Khalil GI, Said R, Eldin S, et al. Fibroblast growth factor ‑ 23 rs7955866 polymorphism and risk of chronic kidney disease. Egypt J Med Hum Genet. 2022;7:1–13.
Abd Al Ridha AM, Kadhim DJ, Alkhazrajy AHA A Cross-Sectional Study of Urinary Neutrophil Gelatinase- Associated Lipocalin and its Association with Steroid Responsiveness in Iraqi Children with Idiopathic Nephrotic Syndrome. J Fac Med Baghdad. 2023;65:163–72.
Hepp N, Folkestad L, Simone M, Lisbeth A, Duno M, Rye N, et al. Bone-microarchitecture and bone-strength in a sample of adults with hypophosphatasia and a matched reference population assessed by HR-pQCT and impact microindentation. Bone. 2022;160:8756–3282.
Palupi-Baroto R, Hermawan K, Murni IK, Nurlitasari T, Prihastuti Y, Sekali DRK, et al. High fibroblast growth factor 23 as a biomarker for severe cardiac impairment in children with chronic kidney disease: A single tertiary center study. Int J Nephrol Renovasc Dis. 2021;14:165–71.
Jin D, Jia M, Xie Y, Lin L, Qiu H, Lu G. Impact of klotho on the expression of SRGAP2a in podocytes in diabetic nephropathy. BMC Nephrol. 2022;23:1–12.
Fernandez-Fernandez B, Izquierdo MC, Valiño-Rivas L, Nastou D, Sanz AB, Ortiz A, et al. Albumin downregulates Klotho in tubular cells. Nephrol Dial Transplant. 2018;33:1712–22.
Gu J, Shi J, Chen X, Mao J, You H, Chen J. High sodium reduced the expression of PTH1R and Klotho by inhibiting 1, 25 (OH) 2 D 3 synthesis in cultured proximal tubule epithelial cells. Ann Transl Med. 2022;25:1–20.
Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, et al. Effects of Sevelamer Carbonate in Patients with CKD and Proteinuria: The ANSWER Randomized Trial. Am J Kidney Dis. 2019;74:338–350.
Al‑Mendalawi MD. Thyroid Profile in Idiopathic Childhood Steroid ‑ Sensitive Nephrotic Syndrome. Med J Dr DY Patil Vidyapeeth. 2022;15:953.
Tomo S, Birdi A, Yadav D, Chaturvedi M, Sharma P. Klotho: a possible role in the pathophysiology of nephrotic syndrome. Electron J Int Fed Clin Chem Lab Med. 2022;33:3–10.
Mohammed A, Alridha A, Kadhim DJ, Hussein A, Alkhazrajy A. Association of the rs1128503 and rs1045642 polymor- phisms in the MDR-1 gene with steroid responsiveness in Iraqi children with idiopathic nephrotic syndrome. Pharm Sci Asia. 2023;50:187–95.
Zeng D, Zha A, Lei Y, Yu Z, Cao R, Li L, et al. Correlation of Serum FGF23 and Chronic Kidney Disease- Mineral and Bone Abnormality Markers with Cardiac Structure Changes in Maintenance Hemodialysis Patients. Evidence-Based Complement Altern Med. 2023;23:1–7.
Hussain I, Tandi R, Singh G, Kaur G, Dodda S. Correlation of FGF-23 With Biochemical Markers and Bone Density in Chronic Kidney Disease- Bone Mineral Density Disorder. Cureus. 2023;15:1–11
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
